An EGFR-Induced Drosophila Lung Tumor Model Identifies Alternative Combination Treatments

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Lung cancer is a leading cause of cancer mortality.
• Epidermal Growth Factor Receptor (EGFR) gene mutations drive lung tumor development.
• Personalized therapies for EGFR-mutated lung cancer face limitations due to toxicity and resistance.

Purpose of the Study:

• To identify novel therapeutic strategies for EGFR-driven lung cancer using a Drosophila melanogaster model.
• To screen FDA-approved compounds for efficacy against EGFR-induced lung hyperplasia.
• To discover synergistic drug combinations for enhanced lung cancer treatment.

Main Methods:

• Constitutively active EGFR (EGFR^CA) was expressed in the airway system of Drosophila melanogaster.
• A whole-animal screening approach was employed using a library of 1,000 FDA-approved compounds.
• Compounds were screened for their ability to rescue EGFR^CA-induced lethality, both independently and in combination with afatinib.

Main Results:

• Ectopic EGFR^CA expression induced severe airway hyper- and metaplasia, leading to premature death.
• Tyrosine kinase inhibitors (TKIs) afatinib, gefitinib, and ibrutinib were identified as effective single agents.
• Bazedoxifene demonstrated synergistic efficacy when combined with a subtherapeutic dose of afatinib.

Conclusions:

• Drosophila whole-animal screening is a viable approach for identifying EGFR inhibitors and synergistic compounds.
• Targeting EGFR in combination with STAT signaling presents a promising therapeutic strategy for lung tumors.
• Combination therapies, such as EGFR inhibitors with bazedoxifene, offer potential for overcoming treatment resistance in lung cancer.